Untersuchungen zur Bioverfügbarkeit von Midodrin und 2,5- Dimethoxyphenyl-ß-aminoethanol-hydrochlorid [The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride]

URN to cite this document:

urn:nbn:de:bvb:355-epub-268473 Copy

DOI to cite this document:

10.5283/epub.26847 Copy

Grobecker, H. ; Kees, Frieder K. ; Linden, M. ; Schrader, E. ; Welte, S.

Preview

PDF (811kB)

Date of publication of this fulltext: 29 Nov 2012 12:40

---

Alternative links to fulltext:Pubmed

---

Details

Item type:	Article
Journal or Publication Title:	Arzneimittel-Forschung
Publisher:	Editio-Cantor-Verl./Thieme
Volume:	37
Number of Issue or Book Chapter:	4
Page Range:	pp. 447-450
Date:	1987
Institutions:	Chemistry and Pharmacy > Institute of Pharmacy > Pharmacology and Toxicology (Prof. Schlossmann, formerly Prof. Seifert)
Identification Number:	Value Type 2440455 PubMed ID
Classification:	Notation Type Administration, Oral MESH Adrenergic alpha-Agonists/metabolism MESH Adult MESH Biological Availability MESH Chromatography, High Pressure Liquid MESH Ethanolamines/metabolism MESH Humans MESH Injections, Intravenous MESH Kinetics MESH Male MESH Midodrine/metabolism MESH
Dewey Decimal Classification:	600 Technology > 615 Pharmacy
Status:	Published
Refereed:	Yes, this version has been refereed
Created at the University of Regensburg:	Unknown
Item ID:	26847

Preview

Export bibliographical data

ASCII CitationAtomBibTeXData Cite XMLDataCite XML OAIDublin CoreEndNoteHTML CitationJSON LDMETSMODSOpenAPCRDF+N-TriplesRDF+N3RDF+XMLReferReference ManagerSimple MetadataXMLxMetaDissPlus

---

Abstract

The pharmacokinetics of midodrin (alpha-2,5-dimethoxyphenyl-beta-glycinamidoethanol hydrochloride, ST 1085) and its main metabolite ST 1059 (alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride) have been investigated in 12 male healthy volunteers. 2.5 mg midodrin hydrochloride were applied intravenously, as drinking solution or as tablet (Gutron) according to a randomized cross-over design. ...

Abstract

The pharmacokinetics of midodrin (alpha-2,5-dimethoxyphenyl-beta-glycinamidoethanol hydrochloride, ST 1085) and its main metabolite ST 1059 (alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride) have been investigated in 12 male healthy volunteers. 2.5 mg midodrin hydrochloride were applied intravenously, as drinking solution or as tablet (Gutron) according to a randomized cross-over design. Plasma and urine samples collected up to 24 h after application were analyzed by high-performance liquid chromatography with fluorescence detection. The mean maximum concentration in plasma for midodrin was ca. 10 ng/ml 20-30 min after oral administration, for ST 1059 ca. 5 ng/ml after 1 h. Midodrin was eliminated with a terminal half-life of 0.5 h. The half-life of ST 1059 was determined to be 3 h. The mean area under the plasma-level vs. time curve (AUC) of ST 1059 after administration of 2.5 mg midodrin i.v. was 28.7 ng X h/ml, and as drinking solution or as tablet 25.7 and 25.6 ng X h/ml, respectively. The data of 10 volunteers could be used for the calculations of the bioavailability of ST 1059 by the AUC. Assuming an interval of equivalence of 0.75-1.25 because of the relatively small number of volunteers, the three galenical formulations are considered to be equivalent.

---

---

Metadata last modified: 25 Nov 2020 15:29

Owner only: item control page

Download Statistics

Download Statistics

Download Statistics

Download Statistics

Downloads

Downloads per month over past year

Altmetric

Altmetric

Altmetric

Alternative Statistics (altmetrics)

More literature (via CORE)

More literature (via CORE)

More literature (via CORE)

More literature (via CORE)